Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02934477 · ClinicalTrials.gov registry record
Prospective Assessment of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis
A clinical trial of Myelofibrosis, sponsored by Center for International Blood and Marrow Transplant Research.
- Recruiting
- Registry status
- 650
- Enrollment target
- 1
- Study location
NCT02934477 is a study of Myelofibrosis that is actively recruiting participants, run by Center for International Blood and Marrow Transplant Research. The registered enrollment target is 650 participants, above the 185-participant average among 61 other Myelofibrosis trials with a reported enrollment target (251% higher). The trial reports 1 study location across 1 state.
The verdict
NCT02934477, a study of Myelofibrosis, is actively recruiting participants, sponsored by Center for International Blood and Marrow Transplant Research.
- RECRUITING
- Registry status
- 650 participants
- Enrollment target
- 1
- Study location
Study Summary
This observational study will compare outcomes of a prospectively-enrolled cohort of Hematopoietic Stem Cell Transplant (HCT) recipients with outcomes of a cohort of age-matched historical non-HCT controls. Patients undergoing alloHCT will receive HCT in a US transplant center and be reported to the Center for International Blood and Marrow Transplant Research (CIBMTR) using well-established CIBMTR report forms and data collection procedures as well as a study-specific supplemental form. Data on the historical non-HCT controls will be collected at 14 US academic centers. These centers will provide data on all consecutive patients with PMF, post-ET MF, or post-PV MF referred to their institutions between 2000 and 2012.
Conditions Studied
Interventions
- OTHER Hematopoietic Stem Cell Transplant
Study Locations (1)
Minnesota
- Center for International Blood and Marrow Transplant Research - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 650 participants |
| Start Date | 2016-11 |
| Est. Completion | 2027-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02934477
The ClinicalTrials.gov registry entry for NCT02934477 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 650 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 185-participant average among 61 other Myelofibrosis trials with a reported enrollment target (251% higher). The listed sponsor is Center for International Blood and Marrow Transplant Research, which has 29 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Myelofibrosis appearing as the primary indexed condition, and to 1 intervention - of which Hematopoietic Stem Cell Transplant is the first listed.
NCT02934477 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT02934477 about?
NCT02934477 is a clinical study titled "Prospective Assessment of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis". This observational study will compare outcomes of a prospectively-enrolled cohort of Hematopoietic Stem Cell Transplant (HCT) recipients with outcomes of a cohort of age-matched historical non-HCT controls. Patients undergoing alloHCT will receive HCT in a US transplant center and be reported to the...
What is the current status of trial NCT02934477?
This trial is currently recruiting. The enrollment target is 650 participants. The study started on 2016-11. Estimated completion is 2027-10.
What conditions does trial NCT02934477 study?
This clinical trial studies the following conditions: Myelofibrosis.
What interventions are being tested in trial NCT02934477?
The interventions under investigation include: Hematopoietic Stem Cell Transplant (OTHER).
Who is sponsoring clinical trial NCT02934477?
This trial is sponsored by Center for International Blood and Marrow Transplant Research, which has 29 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02934477 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myelofibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
RECRUITING · Phase 1
-
Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis
RECRUITING · Phase 2
-
Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
RECRUITING · Phase 3
-
Momelotinib During and After HCT in Myelofibrosis
RECRUITING · Phase 1
-
A Study of Ruxolitinib in Combination With Ulixertinib in People With Myelofibrosis
RECRUITING · Phase 1
-
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.